19.17
0.09 (0.47%)
| Penutupan Terdahulu | 19.08 |
| Buka | 18.80 |
| Jumlah Dagangan | 1,914,153 |
| Purata Dagangan (3B) | 1,488,972 |
| Modal Pasaran | 1,823,067,008 |
| Harga / Pendapatan (P/E Ke hadapan) | 14.97 |
| Harga / Jualan (P/S) | 0.670 |
| Harga / Buku (P/B) | 3.48 |
| Julat 52 Minggu |
| Margin Keuntungan | -29.43% |
| Margin Operasi (TTM) | -3.81% |
| EPS Cair (TTM) | -8.39 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -1.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 149.92% |
| Nisbah Semasa (MRQ) | 0.970 |
| Aliran Tunai Operasi (OCF TTM) | 164.20 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 310.66 M |
| Pulangan Atas Aset (ROA TTM) | -1.74% |
| Pulangan Atas Ekuiti (ROE TTM) | -61.58% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Fortrea Holdings Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.67 |
|
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.40% |
| % Dimiliki oleh Institusi | 101.90% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| SMITH DAVID ROSS | - | - | 0 | 0 |
| Jumlah Keseluruhan Kuantiti Bersih | 0 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 0 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| SMITH DAVID ROSS | Pengarah | 20 Jul 2026 | Pelaksanaan pilihan | 6,598 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |